Full Text View
Tabular View
No Study Results Posted
Related Studies
Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis
This study has been terminated.
Study NCT00506519   Information provided by LEO Pharma

First Received on July 23, 2007.   Last Updated on August 23, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Disseminated Intravascular Coagulation
Sepsis
More general conditions related to this trial
Blood Coagulation Disorders
Hematologic Diseases
Hemorrhagic Disorders
Infection
Inflammation
Pathologic Processes
Systemic Inflammatory Response Syndrome
Thrombophilia
Interventions listed in this trial
antithrombin alfa (INN name)
Additional drug interventions recognized in this trial
Antithrombin III
Antithrombin Proteins
Antithrombins
More general drug interventions related to this trial
Anticoagulants
Enzyme Inhibitors
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Serine Proteinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
LEO Pharma


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services